UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
------------------------
Date of Report (Date of earliest event reported): May 5, 2004
IMPAX LABORATORIES, INC.
----------------------------------------------------------------
(Exact name of Registrant as specified in its charter)
Delaware 0-27354 65-0403311
- ---------------------------- ------------------------ -------------------
(State or other jurisdiction (Commission File Number) (I.R.S. Employer
of incorporation) Identification No.)
30381 Huntwood Avenue
Hayward, CA 94544
------------------------------------------------------------
(Address of principal executive offices, including zip code)
Registrant's telephone number, including area code: (510) 476-2000
--------------
Item 9. Regulation FD Disclosure.
Item 12. Results of Operations and Financial Condition.
The following information is being furnished pursuant to Item 12 -
Results of Operations and Financial Condition and pursuant to Item 9 -
Regulation FD Disclosure on this Form 8-K. Such information, including the
Exhibit attached hereto, shall not be deemed "filed" for purposes of Section 18
of the Securities Exchange Act of 1934.
On May 5, 2004, the Company issued a press release announcing its
financial results for the quarter ended March 31, 2004. A copy of that press
release is attached hereto as Exhibit 99.1 and is incorporated herein by
reference.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Impax Laboratories, Inc.
Date: May 5, 2004 By: /s/ Cornel C. Spiegler
-------------------------------
Cornel C. Spiegler
Chief Financial Officer